X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA Share Price   (TORR)

Here is the latest stock price and chart of Torrent Pharma. For more details, see the Torrent Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.

REFRESH
Live BSE Quotes Oct 23, 2017 03:06:00 PM
Price (Rs)1,371.30 Open (Rs) 1,362.00 High (Rs) 1,411.45 Low (Rs) 1,362.00
% Change1.07 Volume 18,215 Value (Rs) 24,978,230 52-Week H/L 1,640.95 / 1,143.50
Live NSE Quotes Oct 23, 2017 3:09:58 PM
Price (Rs)1,373.40 Open (Rs) 1,360.00 High (Rs) 1,413.70 Low (Rs) 1,360.00
% Change0.80 Volume 209,993 Value (Rs) 292,673,544 52-Week H/L 1,639.95 / 1,141.95
Valuation
EPS (Rs)* 49.04 P/E Ratio (x) 27.96 Market Cap (Rs m) 232,106.24 P/BV (x) 6.85
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
Torrent Pharma Share Price Chart (Rs) - 1 Year
Loading...
 
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new


Today's Market

Sensex Pares Gains; Telecom Stocks Rally(01:30 pm)

After opening the day on a firm note, the Indian share markets pared its morning gains to trade flat. Sectoral indices are trading mixed, with stocks in the realty sector.

Related Views On News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Timeless Stocks on the Electric Car Assembly Line(The 5 Minute Wrapup)

Oct 10, 2017

Are they on their way to create Coca Cola-like wealth?

Why Merger of Public Sector Banks Continues to Be a Bad Idea(Vivek Kaul's Diary)

Oct 10, 2017

There is enough research evidence that suggests that most mergers don't work.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

Mutual Funds Re-categorised... But What About Stocks?(Daily Profit Hunter)

Oct 11, 2017

The market regulator can solve systemic issues but you must tackle the behavioral biases on your own.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - MYLAN COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS